DK1173205T3 - Oral formulering til ileum-indgivelse, omfattende en forbindelse til inhibering af ileum-galdesyretransporten - Google Patents

Oral formulering til ileum-indgivelse, omfattende en forbindelse til inhibering af ileum-galdesyretransporten

Info

Publication number
DK1173205T3
DK1173205T3 DK00928046T DK00928046T DK1173205T3 DK 1173205 T3 DK1173205 T3 DK 1173205T3 DK 00928046 T DK00928046 T DK 00928046T DK 00928046 T DK00928046 T DK 00928046T DK 1173205 T3 DK1173205 T3 DK 1173205T3
Authority
DK
Denmark
Prior art keywords
ileum
bile acid
inhibitor compound
compound
inhibiting
Prior art date
Application number
DK00928046T
Other languages
English (en)
Inventor
Ann-Margret Lindqvist
Bertil Abrahamsson
Anna-Lena Ungell
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1173205T3 publication Critical patent/DK1173205T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00928046T 1999-04-19 2000-04-19 Oral formulering til ileum-indgivelse, omfattende en forbindelse til inhibering af ileum-galdesyretransporten DK1173205T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9901387A SE9901387D0 (sv) 1999-04-19 1999-04-19 New pharmaceutical foromaulations
PCT/SE2000/000755 WO2000062810A1 (en) 1999-04-19 2000-04-19 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
EP00928046A EP1173205B1 (en) 1999-04-19 2000-04-19 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport

Publications (1)

Publication Number Publication Date
DK1173205T3 true DK1173205T3 (da) 2005-08-08

Family

ID=20415263

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00928046T DK1173205T3 (da) 1999-04-19 2000-04-19 Oral formulering til ileum-indgivelse, omfattende en forbindelse til inhibering af ileum-galdesyretransporten

Country Status (27)

Country Link
EP (1) EP1173205B1 (da)
JP (1) JP2002542208A (da)
KR (1) KR20010108516A (da)
CN (1) CN1348384A (da)
AT (1) ATE296641T1 (da)
AU (1) AU767425B2 (da)
BR (1) BR0009835A (da)
CA (1) CA2379105A1 (da)
CZ (1) CZ20013743A3 (da)
DE (1) DE60020551T2 (da)
DK (1) DK1173205T3 (da)
EE (1) EE04607B1 (da)
ES (1) ES2241603T3 (da)
HK (1) HK1042850A1 (da)
HU (1) HUP0200793A3 (da)
IL (1) IL145871A0 (da)
IS (1) IS2161B (da)
NO (1) NO20015063D0 (da)
NZ (1) NZ514264A (da)
PL (1) PL351186A1 (da)
PT (1) PT1173205E (da)
SE (1) SE9901387D0 (da)
SI (1) SI1173205T1 (da)
SK (1) SK15282001A3 (da)
TR (1) TR200103033T2 (da)
WO (1) WO2000062810A1 (da)
ZA (1) ZA200108539B (da)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
IL151150A0 (en) * 2001-01-31 2003-04-10 Roehm Gmbh Multiparticulate drug form comprising at least two differently coated pellet forms
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
TWI331143B (en) 2001-09-08 2010-10-01 Astrazeneca Uk Ltd Benzothiadiazepine derivatives, process for preparing them, and pharmaceutical composition comprising them
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0216321D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
BRPI0912683A2 (pt) 2008-05-15 2016-01-26 Transmolecular Inc tratamento de tumores metastáticos
CN102316872B (zh) * 2008-11-26 2016-12-21 萨蒂奥根制药公司 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
US8318663B2 (en) 2008-11-26 2012-11-27 Satiogen Pharmaceuticals, Inc. Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agent
GB0900350D0 (en) * 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
CN102844044B (zh) 2010-02-04 2016-10-26 摩尔弗泰克有限公司 氯毒素多肽和结合物及其应用
EP2569330B1 (en) 2010-05-11 2016-09-28 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates, and methods for their use
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
AU2011326871B2 (en) 2010-11-08 2015-02-12 Albireo Ab IBAT inhibitors for the treatment of liver diseases
PT2637646T (pt) 2010-11-08 2016-08-17 Albireo Ab Uma combinação farmacêutica que compreende um inibidor do ibat e um sequestrador de ácido biliar
SG11201401816SA (en) * 2011-10-28 2014-05-29 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
EA201891154A1 (ru) * 2011-10-28 2019-02-28 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
AU2013359429A1 (en) 2012-12-10 2015-07-09 Fred Hutchinson Cancer Research Center Methods for screening
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
JP6751020B2 (ja) 2014-06-25 2020-09-02 Eaファーマ株式会社 固形製剤及びその着色防止又は着色低減方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
CN105362244A (zh) * 2015-11-26 2016-03-02 青岛海之源智能技术有限公司 考来烯胺缓释片及制备方法
CN108601745B (zh) 2016-02-09 2021-12-07 阿尔比里奥公司 口服考来烯胺制剂及其用途
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
WO2017138877A1 (en) 2016-02-09 2017-08-17 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
CA3021011A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
CA3071182A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations and use thereof
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES2942443T3 (es) 2018-06-05 2023-06-01 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
TWI823954B (zh) 2018-06-20 2023-12-01 瑞典商艾爾比瑞歐公司 奧德維希百(odevixibat)之結晶修飾物
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
CA3127408A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP7504109B2 (ja) 2019-02-06 2024-06-21 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
BR112021015809A2 (pt) 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Resposta dependente de genótipo e dose a um asbti em pacientes com deficiência de bomba de exportação de sal biliar
MX2022006731A (es) 2019-12-04 2022-06-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar.
AR120682A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
JP2023504643A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
TW202134222A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
JP2023504644A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP2023504647A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
PT4069360T (pt) 2019-12-04 2024-03-06 Albireo Ab Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CN116157389A (zh) 2020-08-03 2023-05-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
KR20230106651A (ko) 2020-11-12 2023-07-13 알비레오 에이비 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
CA3198216A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
AU2023255249A1 (en) 2022-04-22 2024-10-17 Albireo Ab Subcutaneous administration of an asbt inhibitor
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
US20240067617A1 (en) 2022-07-05 2024-02-29 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US20240207286A1 (en) 2022-12-09 2024-06-27 Albireo Ab Asbt inhibitors in the treatment of renal diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA941003B (en) * 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
TW289020B (da) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤

Also Published As

Publication number Publication date
JP2002542208A (ja) 2002-12-10
DE60020551D1 (de) 2005-07-07
HUP0200793A3 (en) 2004-07-28
SE9901387D0 (sv) 1999-04-19
TR200103033T2 (tr) 2002-03-21
IS6109A (is) 2001-10-16
EP1173205A1 (en) 2002-01-23
SK15282001A3 (sk) 2002-04-04
WO2000062810A1 (en) 2000-10-26
IS2161B (is) 2006-11-15
ZA200108539B (en) 2003-01-17
EE200100545A (et) 2003-02-17
NZ514264A (en) 2003-10-31
IL145871A0 (en) 2002-07-25
NO20015063L (no) 2001-10-18
KR20010108516A (ko) 2001-12-07
AU767425B2 (en) 2003-11-13
ATE296641T1 (de) 2005-06-15
EP1173205B1 (en) 2005-06-01
HUP0200793A2 (hu) 2002-07-29
CZ20013743A3 (cs) 2002-01-16
PT1173205E (pt) 2005-10-31
DE60020551T2 (de) 2006-03-23
ES2241603T3 (es) 2005-11-01
CN1348384A (zh) 2002-05-08
NO20015063D0 (no) 2001-10-18
SI1173205T1 (en) 2005-10-31
HK1042850A1 (en) 2002-08-30
PL351186A1 (en) 2003-03-24
AU4633500A (en) 2000-11-02
BR0009835A (pt) 2002-01-08
EE04607B1 (et) 2006-04-17
CA2379105A1 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
DK1173205T3 (da) Oral formulering til ileum-indgivelse, omfattende en forbindelse til inhibering af ileum-galdesyretransporten
SE0003766D0 (sv) Novel formulation
NZ514574A (en) Novel method of treatment
BG105568A (en) Pharmaceutical compositions for modified release of an insulin sensitiser and another antidiabetic agent
WO2001078701A3 (en) Method and compositions for preventing hormone induced adverse effects
EE200200086A (et) Reniin-angiotensiini süsteemi inhibiitori kasutamine, kombineeritud produkt ja meetod kardiovaskulaarsete haigusjuhtude ärahoidmiseks
HUP9803044A2 (hu) Ibuprofentartalmú készítmény
BG104680A (en) Celecoxib compositions
IL124459A0 (en) Antagonists of gonadotropin releasing hormone
MX9804850A (es) Antagonistas de hormona liberadora de gonadotropina.
HUP0001162A2 (hu) Pirrolo-benzodiazepin-, -kinoxalin-, -pirazin-származékok és az ezeket tartalmazó gyógyszerkészítmények
GEP20043383B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds
DE60030283D1 (de) Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
TW349865B (en) Therapeutic agent for hemorrhoidal diseases
AP1901A (en) Pharmaceutical composition for modified release insulin sensitiser.
BG108144A (en) New use
EP1347754A4 (en) COMPOSITIONS FOR PREVENTION OF ADHESION
BG104692A (en) Extended release tiagabine formulation
DK1071425T3 (da) Behandling af depression og farmaceutiske præparater dertil
AU2003241629A1 (en) An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
UA4313U (uk) Спосіб лікування системного червоного вовчака
TR200102262T2 (tr) Koroner müdahale ile ilgili kardiovasküler olayların önlenmesi veya azaltılması için yöntem.
TR200102245T2 (tr) Koroner müdahale ile ilgili kardiovasküler olayların önlenmesi veya azaltılması için yöntem.
UA4316U (uk) Спосіб лікування системного червоного вовчака